lavomaks-tabletki-pokrytye-obolochkoj-125mg-n6

35.00$

Category:

Product Description

lavomaks-tabletki-pokrytye-obolochkoj-125mg-n6

FREE SHIPPING TO ALL COUNTRIES!!!

I  ACCEPT  PAYPAL

SHIPPING:
Europe delivered time is 8 — 12 business days.

Usa/canada delivered time 15-20 business days.

Australia/Asia delivered time 15-26 business days.

For any possible questions, please, contact me!
NEW
100 % ORIGINAL
TRACKING NUMBER
THANK YOU FOR VISITING MY LOT
It is very important !!! Item will be shipped from Russia for 2-3 days and free shipping takes 14 to 21 days

Free shipping

NEW
100 % ORIGINAL

TRACKING NUMBER

THANK YOU FOR VISITING MY LOT

dosage form
Film-coated tablets from yellow to orange, round; in cross section showed two layers; orange tablet core
Composition
tilorona 125 mg

Excipients: magnesium hydroxycarbonate hydrate, povidone (polyvinylpyrrolidone, low molecular weight Medical), calcium stearate, colloidal silicon dioxide (Aerosil), beeswax, vaseline oil, sucrose, talc, tropeolin O, titanium dioxide, polyethylene glycol, high molecular weight of 6000 (to obtain tablets weighing 0.39 g ).
pharmachologic effect
The antiviral and immunomodulatory drug. Lavomaks® stimulates formation in the body -? -?.-Interferon. In response to the Lavomax interferon produced mainly intestinal epithelial cells, hepatocytes, T-lymphocytes, and neutrophils.

After taking the drug inside a maximum production of interferon is defined in the sequence gut-liver-blood through the 4-24 hours. Lavomaks® has immunomodulatory and antiviral effect. It stimulates bone marrow stem cells, in a dose dependent increases antibody reduces the degree of immunosuppression, restores ratio T-helpers / T-suppressors.

Effective against a variety of viral infections, including influenza virus, and other acute respiratory viral infections, hepatitis viruses and herpes, cytomegalovirus and neurotropic viruses.

The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells as a result of the suppressed virus reproduction.
Pharmacokinetics
Suction

After taking the drug inside tilorona it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%.

Distribution

Binding to plasma proteins — about 80%.

Metabolism and excretion

Tilorona no biotransformation and accumulates in the body. Displayed virtually unchanged in the feces (approximately 70%) and urine (about 9%). T1 / 2 is 48 h.
Side effects
From the digestive system: in some cases — symptoms of dyspepsia.

Other: possible intermittent fever, allergic reactions.
sale Properties
No prescription
Special conditions
Lavomaks® compatible with conventional antibiotic agents and the treatment of viral and bacterial infections.
testimony
The drug used in adults for the treatment of:

— Viral hepatitis A, B and C;

— Herpes infection;

— Cytomegalovirus infection.

In the combined therapy:

— Infectious-allergic and viral encephalomyelitis (multiple sclerosis, leykoentsefality, uveoentsefality);

— Urogenital and respiratory chlamydia;

— NGU;

— Pulmonary tuberculosis.

For the treatment and prevention of influenza and other acute respiratory viral infections.
Contraindications
— Pregnancy;

— Lactation (breastfeeding);

— Children up to age 18;

— Hypersensitivity to the drug.
Drug interactions
Compatible with antibiotics and traditional means of treatment of viral and bacterial diseases.

Clinically significant drug interactions with antibiotics Lavomaks®, traditional means of treatment of viral and bacterial diseases, alcohol is not revealed.
Dosage
The drug is taken orally, after meals. In the treatment of influenza and other acute respiratory viral infections — in the first two days of illness — 125 mg, then — in a day 125 mg. Heading dose — 750 mg (per course of treatment — 6 tablets of 125 mg). For the prevention of influenza and other acute respiratory viral infections — 125 mg 1 time per week for 6 weeks. In the course of treatment — 6 tablets of 125 mg. For the treatment of viral hepatitis A — on the first day of 125 mg 2 times, then 125 mg every other day. Heading dose of 1.25 g (per course of treatment — 10 tablets of 125 mg). For the treatment of acute hepatitis B — the first and second days of 125 mg, then 125 mg every other day. Heading dose of 2 g (per course of treatment — 16 125 mg tablets), with a protracted course of hepatitis B — 125 mg in the first 2 days, then — 125 mg a day. Heading dose of 2.5 g (per course of treatment — 20 tablets of 125 mg). In chronic hepatitis B — initial phase of treatment (2.5 g) — the first two days of 125 mg, and then — 125 mg a day. Continuation phase (from 1.25 g to 2.5 g) — 125 mg per week. Heading dose of the drug Lavomaks® from 3.75 to 5 g (on a course of treatment — from 30 to 40 tablets of 125 mg), the duration of treatment is 3.5-6 months depending on the results of biochemical, immunological. morphological studies, reflecting the degree of activity of the process. In acute hepatitis C — the first and second days of 125 mg, then 125 mg every other day. Course dose — 2.5 g (per course of treatment — 20 tablets of 125 mg). In chronic hepatitis C — the initial phase of treatment (2.5 g) — the first two days of 250 mg. then 125 mg every other day. Continuation phase (2.5 g) — 125 mg per week. Heading dose Lavomaks® product — 5 g (on a course of treatment — 40 tablets of 125 mg). Duration of treatment — 6 months depending on the results of biochemical, immunological, morphological markers of activity of the process. For the treatment of herpes, cytomegalovirus infection — the first two days of 125 mg followed by 125 mg daily. Course dose — 2.5 g (per course of treatment — 20 tablets of 125 mg). When urogenital and respiratory chlamydia, NGU — the first two days of 125 mg followed by 125 mg daily. Heading dose — 1.25 g (per course of treatment — 10 tablets of 125 mg). In the complex treatment of pulmonary tuberculosis — the first two days of 250 mg followed by 125 mg every other day. Heading dose of 2.5 g (per course of treatment — 20 tablets of 125 mg). In the complex treatment of infections neyrovirusnyh dose set individually, a course of treatment is 4 weeks.